These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 34410435)

  • 41. [
    Yang L; Xu S; Cheng L; Gao C; Cao S; Chang Z; Wang K
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4051-4063. PubMed ID: 37542659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of
    Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
    Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
    Hirmas N; Hamacher R; Sraieb M; Ingenwerth M; Kessler L; Pabst KM; Barbato F; Lueckerath K; Kasper S; Nader M; Schildhaus HU; Kesch C; von Tresckow B; Hanoun C; Hautzel H; Aigner C; Glas M; Stuschke M; Kümmel S; Harter P; Lugnier C; Uhl W; Niedergethmann M; Hadaschik B; Grünwald V; Siveke JT; Herrmann K; Fendler WP
    J Nucl Med; 2023 May; 64(5):711-716. PubMed ID: 36581374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [
    Siripongsatian D; Promteangtrong C; Kunawudhi A; Kiatkittikul P; Boonkawin N; Chinnanthachai C; Jantarato A; Chotipanich C
    Mol Imaging Biol; 2022 Oct; 24(5):818-829. PubMed ID: 35486293
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Fu H; Wu J; Huang J; Sun L; Wu H; Guo W; Qiu S; Chen H
    Radiology; 2022 Aug; 304(2):397-405. PubMed ID: 35536131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Head-to-Head Comparison of [
    Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
    Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Added Value of
    Gu B; Xu X; Zhang J; Ou X; Xia Z; Guan Q; Hu S; Yang Z; Song S
    J Nucl Med; 2022 Jun; 63(6):875-881. PubMed ID: 34593594
    [No Abstract]   [Full Text] [Related]  

  • 49. Dual targeting PET tracer [
    Wang R; Jakobsson V; Wang J; Zhao T; Peng X; Li B; Xue J; Liang N; Zhu Z; Chen X; Zhang J
    Theranostics; 2023; 13(9):2979-2992. PubMed ID: 37284441
    [No Abstract]   [Full Text] [Related]  

  • 50. Head-to-Head Comparison of
    Promteangtrong C; Siripongsatian D; Jantarato A; Kunawudhi A; Kiatkittikul P; Yaset S; Boonkawin N; Chotipanich C
    J Nucl Med; 2022 Aug; 63(8):1155-1161. PubMed ID: 34857655
    [No Abstract]   [Full Text] [Related]  

  • 51.
    Dendl K; Koerber SA; Finck R; Mokoala KMG; Staudinger F; Schillings L; Heger U; Röhrich M; Kratochwil C; Sathekge M; Jäger D; Debus J; Haberkorn U; Giesel FL
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4089-4100. PubMed ID: 34050777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of [
    Civan C; Kuyumcu S; Has Simsek D; Sanli O; Isik EG; Ozkan ZG; Hurdogan O; Sanli Y
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):852-861. PubMed ID: 37803246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Head-to-head comparison of [
    Liu S; Feng Z; Xu X; Ge H; Ju X; Wu X; Song S
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1521-1531. PubMed ID: 36624168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 68 Ga-FAPI-04 PET/CT for the Evaluation of Cholangiocarcinoma : Comparison With 18 F-FDG PET/CT and Abdominal 68 Ga-FAPI-04 PET/MR.
    Zhang Z; Cheng C; Jiang H; Pan G; Yu Y; Jin G; Zuo C
    Clin Nucl Med; 2024 May; 49(5):409-418. PubMed ID: 38465929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The performance of
    Jiang Y; Wen B; Li C; Tian Y; Xiao Z; Xu K; Xing D; Yu Z; Huang J; Jia J; He Y
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2114-2126. PubMed ID: 36808001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the diagnostic efficacy of
    Zhang Z; Jia G; Pan G; Cao K; Yang Q; Meng H; Yang J; Zhang L; Wang T; Cheng C; Zuo C
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2877-2888. PubMed ID: 35243518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Lanzafame H; Mavroeidi IA; Pabst KM; Desaulniers M; Ingenwerth M; Hirmas N; Kessler L; Nader M; Bartel T; Leyser S; Barbato F; Schuler M; Bauer S; Siveke JT; Herrmann K; Hamacher R; Fendler WP
    J Nucl Med; 2024 Jun; 65(6):880-887. PubMed ID: 38724279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of
    Güzel Y; Kaplan İ
    Hell J Nucl Med; 2023; 26(1):26-34. PubMed ID: 37031420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of [
    Miao Y; Feng R; Guo R; Huang X; Hai W; Li J; Yu T; Qu Q; Zhang M; Shangguan C; Mi J; Zhu Z; Li B
    Eur Radiol; 2023 Jun; 33(6):4355-4366. PubMed ID: 36522509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.